Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Purchased by Millennium Management LLC

Millennium Management LLC lifted its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 14.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,586,067 shares of the company's stock after buying an additional 457,179 shares during the quarter. Millennium Management LLC owned approximately 1.58% of Gossamer Bio worth $3,244,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lazard Asset Management LLC increased its holdings in Gossamer Bio by 7,992.6% during the 4th quarter. Lazard Asset Management LLC now owns 107,470 shares of the company's stock worth $97,000 after purchasing an additional 106,142 shares during the period. Jefferies Financial Group Inc. acquired a new stake in Gossamer Bio in the fourth quarter worth about $90,000. Graham Capital Management L.P. purchased a new position in shares of Gossamer Bio in the fourth quarter worth about $32,000. Fullcircle Wealth LLC purchased a new position in shares of Gossamer Bio in the fourth quarter worth about $43,000. Finally, Bank of America Corp DE raised its stake in shares of Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock worth $77,000 after purchasing an additional 43,866 shares during the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on GOSS. The Goldman Sachs Group lifted their price target on Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday, May 16th. Wedbush reiterated an "outperform" rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday, May 16th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Gossamer Bio in a research report on Tuesday, March 18th.

Gossamer Bio Stock Performance

GOSS stock traded up $0.04 during trading on Wednesday, hitting $1.26. 1,430,068 shares of the company traded hands, compared to its average volume of 1,554,293. The company has a market cap of $286.40 million, a PE ratio of -3.94 and a beta of 1.85. Gossamer Bio, Inc. has a 1 year low of $0.50 and a 1 year high of $1.55. The stock's 50-day simple moving average is $1.01 and its 200 day simple moving average is $1.02. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The business had revenue of $9.89 million during the quarter, compared to analysts' expectations of $3.95 million. On average, equities analysts expect that Gossamer Bio, Inc. will post -0.28 earnings per share for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.